Q: Could you give me your views on this. Company. Thank you
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Is it time to sell gud and move on. It has done nothing in the last 2 years and seems very stagnant.
Q: Have held this company for 10 years and generally has been very good for income.
Short term doldrums or time to sell?
Thank-you.
Short term doldrums or time to sell?
Thank-you.
Q: What is your opinion on CVS? Is it a buy for long terms (3 years)?
Q: TH reported yesterday. What do you think of earnings report ? Sales up 62 % and they have applied for listing on NASDAQ. Stock fell on announcement . Should I buy TH.? Bob
-
iShares Global Healthcare Index ETF (CAD-Hedged) (XHC $64.45)
-
Harvest Healthcare Leaders Income ETF (HHL $7.37)
Q: Hi Everyone at 5i! You have mentioned that HHL is not your favorite ETF in the health care sector. What would you consider to be a more favourable alternative that exhibits better growth and some income as well ? Cheers, Tamara
Q: I'm looking to take advantage of the strengthening CAD and add risk by selling my stake in GUD (break even) and purchasing caredx and gaurdent for a five year holding period. Is this a bad idea? Will recent comments from the White House around healthcare reform help or hurt these companies? Thanks
Q: What is your current thinking on this company for a 1-2 year hold? What do you consider a good entry point if a possible investment?
Thank you
Thank you
Q: Hello
I currently hold full positions of Stryker and Illumina in healthcare. I’m looking for suggestions of a replacement for Knight. Would consider either US or Canadian.
Thank you
Les
I currently hold full positions of Stryker and Illumina in healthcare. I’m looking for suggestions of a replacement for Knight. Would consider either US or Canadian.
Thank you
Les
Q: Good Morning
I am thinking about taking a position in either ABC:us or CYRX:us (or both). ABC pays a reasonable dividend but I am thinking CYRX might have better growth potential. What are your thoughts?
Thanks for your great service
Ian
I am thinking about taking a position in either ABC:us or CYRX:us (or both). ABC pays a reasonable dividend but I am thinking CYRX might have better growth potential. What are your thoughts?
Thanks for your great service
Ian
Q: Your opinion on a 3% holding in HHL for income would be appreciated.
Q: Stock is down after hours. Is it that serious? Is it time to sell?
Q: comments,please,on recent drop in share value.
Q: Thinking of purchasing for a long term hold. Would this be a wise move or is there another company you would prefer? Thanks as always.
Q: Is there a future in this company? Your view would be appreciated.
-
Pfizer Inc. (PFE $25.88)
-
Zoetis Inc. Class A (ZTS $156.62)
-
iShares Global Healthcare Index ETF (CAD-Hedged) (XHC $64.45)
-
iShares U.S. Medical Devices ETF (IHI $62.87)
Q: Good morning 5i, I am still plodding along with asset allocator. I have only Weed left in healthcare having sold GUD, and COV. I need 9% so another 7% after WEED. Happy to buy in $US or $Cdn and looking at XHC, IHI, PFE, ZTS. I appreciate your input. Regards, Ted
Q: Good morning team,
Re: Gud's NCIB:
“Be mindful that the largest beneficiary of the share repurchase program is Jonathan Goodman. Even if he does not participate, the reduction of shares at a substantial discount to last $10 per share capital raise only serves to increase his percentage control of the company. Like his conflicting interests with his family business (Pharmascience), either way he wins and shareholders lose.
“Rather than engage in financial engineering that principally benefits the CEO, why didn’t the Board consider a partial tender offer for shares at $10? Just give shareholders their money back at the price paid? It’s a fair question. But one that we fully expect the company to ignore.
https://ca.finance.yahoo.com/news/medison-biotech-jonathan-goodman-takes-124100485.html
Comments please,
Thank you!
Re: Gud's NCIB:
“Be mindful that the largest beneficiary of the share repurchase program is Jonathan Goodman. Even if he does not participate, the reduction of shares at a substantial discount to last $10 per share capital raise only serves to increase his percentage control of the company. Like his conflicting interests with his family business (Pharmascience), either way he wins and shareholders lose.
“Rather than engage in financial engineering that principally benefits the CEO, why didn’t the Board consider a partial tender offer for shares at $10? Just give shareholders their money back at the price paid? It’s a fair question. But one that we fully expect the company to ignore.
https://ca.finance.yahoo.com/news/medison-biotech-jonathan-goodman-takes-124100485.html
Comments please,
Thank you!
Q: In doing my research I see 4 strong buys on analysts following the company. It seems to have a target of $35.
What do you think of it? Would you reccomend it as part of a growth portfolio?
Please advise.
Sheldon
What do you think of it? Would you reccomend it as part of a growth portfolio?
Please advise.
Sheldon
Q: Do you see any reason for the big drop today?
Q: Thoughts?
http://www.globenewswire.com/news-release/2019/07/08/1879781/0/en/Knight-Announces-Normal-Course-Issuer-Bid.html
http://www.globenewswire.com/news-release/2019/07/08/1879781/0/en/Knight-Announces-Normal-Course-Issuer-Bid.html